Paula Rodriguez-Otero, MD, PhD

In an interview with Pharmacy Times, Paula Rodríguez-Otero, MD, PhD, discusses patient selection for LINKER-SMM1 and weighs the potential benefits of early linvoseltamab treatment against infection risk in high-risk smoldering multiple myeloma.

In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.

Expert shares the promising potential of linvoseltamab in treating high-risk smoldering multiple myeloma.

Experts discuss the potential of linvoseltamab in treating high-risk smoldering multiple myeloma, highlighting promising early trial results and response rates.